BIIB vs ALNY Comparison: AI Score, Valuation, Performance and Upside
Compare Biogen and Alnylam by Alzheimer's disease therapy validation, RNA interference platform breadth, pipeline conversion rate, revenue trajectory, and which biotech platform offers better long-term growth potential.
Use this Biogen vs Alnylam comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
BIIB and ALNY are closely matched — they split the tracked metrics evenly. BIIB leads on both 1-year return (+52.49%) and forward P/E quality (12.45x vs 20.22x for ALNY), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for ALNY (+58.97%) than for BIIB (+9.86%).
| Metric | BIIB | ALNY |
|---|---|---|
| AI score | 28.9 | 56.8 |
| AI rank | #2383 | #259 |
| Latest close | $202.19 | $271.77 |
| 1M return | +1.30% | -7.58% |
| 6M return | +17.83% | -26.55% |
| 1Y return | +52.49% | -17.14% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BIIB | ALNY |
|---|---|---|
| 1Y ago | $15.37K (+53.7%) started 2025-07-25 | $8.29K (-17.1%) started 2025-07-24 |
| 5Y ago | $6.09K (-39.1%) started 2021-07-26 | $15.26K (+52.6%) started 2021-07-26 |
| 10Y ago | $7.04K (-29.6%) started 2016-07-25 | $41.05K (+310.5%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | BIIB | ALNY |
|---|---|---|
| Market cap | $30.41B | $36.28B |
| Trailing P/E | 22.17 | 68.28 |
| Forward P/E | 12.45 | 20.22 |
| Price/Sales | 1.99 | 8.46 |
| EV/Revenue | 3.29 | 8.36 |
| Analyst target | $226.29 | $432.04 |
| Target upside | +9.86% | +58.97% |
| Metric | BIIB | ALNY |
|---|---|---|
| Revenue growth | 1.90% | 96.40% |
| Earnings growth | 31.10% | N/A |
| EPS growth | +31.10% | N/A |
| FCF margin | +19.43% | +4.78% |
| Operating margin | 22.90% | N/A |
| Profit margin | 13.80% | 12.55% |
| ROIC proxy | 7.70% | 90.36% |
| Return on equity | 7.70% | 90.36% |
| Dividend yield | N/A | 0.00% |
| Beta | 0.16 | 0.27 |
| Debt/equity | 35.18 | 276.20 |
| Current ratio | 3.06 | 3.13 |
| Quick ratio | 2.02 | 2.88 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BIIB | ALNY |
|---|---|---|---|
| 1Y | Growth | +53.73% | -17.14% |
| CAGR | +53.93% | -17.15% | |
| Sharpe ratio | 1.27 | -0.43 | |
| Max drawdown | 14.34% | 45.65% | |
| Max daily drop | 8.17% | 6.87% | |
| Max wkly drop | 12.37% | 14.54% | |
| 5Y | Growth | -39.09% | +52.59% |
| CAGR | -9.45% | +8.83% | |
| Sharpe ratio | -0.25 | 0.31 | |
| Max drawdown | 67.59% | 45.65% | |
| Max daily drop | 8.17% | 17.10% | |
| Max wkly drop | 13.62% | 20.65% | |
| 10Y | Growth | -29.64% | +310.53% |
| CAGR | -3.45% | +15.18% | |
| Sharpe ratio | 0.00 | 0.45 | |
| Max drawdown | 72.66% | 59.95% | |
| Max daily drop | 29.23% | 48.49% | |
| Max wkly drop | 34.30% | 49.44% |
| Category | BIIB | ALNY |
|---|---|---|
| Company | BIIB | ALNY |
| Sector | Healthcare | N/A |
| Industry | Drug Manufacturers - General | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.